New hope for stomach cancer patients who have run out of options
NCT ID NCT07371871
Summary
This study is testing whether combining two existing drugs, TAS-102 and apatinib, can help control advanced stomach cancer when two previous standard treatments have failed. It will enroll about 30 patients to see if the combination can shrink tumors and slow the cancer's growth. The main goal is to measure how well patients respond to this new third-line treatment approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.